Clinical Trial Update: A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing two formulations of romosozumab in postmenopausal osteoporosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Romosozumab (romosozumab)

Snippet

Sponsor: Amgen | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2018-11-08